In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.
Identifieur interne : 002251 ( PubMed/Curation ); précédent : 002250; suivant : 002252In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.
Auteurs : Marie Médoc [France] ; Martine Dhilly [France] ; Lidia Matesic [Australie] ; Jérôme Toutain [France] ; Anwen M. Krause-Heuer [Australie] ; Jérôme Delamare [France] ; Benjamin H. Fraser [Australie] ; Omar Touzani [France] ; Louisa Barré [France] ; Ivan Greguric [Australie] ; Franck Sobrio [France]Source :
- Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging [ 1860-2002 ] ; 2016.
Descripteurs français
- KwdFr :
- Accident vasculaire cérébral (anatomopathologie), Accident vasculaire cérébral (imagerie diagnostique), Acide méthyl-malonique (analogues et dérivés), Acide méthyl-malonique (pharmacocinétique), Acide méthyl-malonique (pharmacologie), Animaux, Apoptose (), Caspase-3 (métabolisme), Caspase-7 (métabolisme), Imagerie moléculaire (), Inhibiteurs des caspases (pharmacocinétique), Inhibiteurs des caspases (pharmacologie), Inhibiteurs des caspases (sang), Isatine (), Isatine (pharmacologie), Modèles animaux de maladie humaine, Mâle, Radiopharmaceutiques (pharmacocinétique), Radiopharmaceutiques (pharmacologie), Radiopharmaceutiques (sang), Rat Sprague-Dawley, Répartition dans les tissus (), Scintigraphie.
- MESH :
- analogues et dérivés : Acide méthyl-malonique.
- anatomopathologie : Accident vasculaire cérébral.
- imagerie diagnostique : Accident vasculaire cérébral.
- métabolisme : Caspase-3, Caspase-7.
- pharmacocinétique : Acide méthyl-malonique, Inhibiteurs des caspases, Radiopharmaceutiques.
- pharmacologie : Acide méthyl-malonique, Inhibiteurs des caspases, Isatine, Radiopharmaceutiques.
- sang : Inhibiteurs des caspases, Radiopharmaceutiques.
- Animaux, Apoptose, Imagerie moléculaire, Isatine, Modèles animaux de maladie humaine, Mâle, Rat Sprague-Dawley, Répartition dans les tissus, Scintigraphie.
English descriptors
- KwdEn :
- Animals, Apoptosis (drug effects), Caspase 3 (metabolism), Caspase 7 (metabolism), Caspase Inhibitors (blood), Caspase Inhibitors (pharmacokinetics), Caspase Inhibitors (pharmacology), Disease Models, Animal, Isatin (chemistry), Isatin (pharmacology), Male, Methylmalonic Acid (analogs & derivatives), Methylmalonic Acid (pharmacokinetics), Methylmalonic Acid (pharmacology), Molecular Imaging (methods), Radionuclide Imaging, Radiopharmaceuticals (blood), Radiopharmaceuticals (pharmacokinetics), Radiopharmaceuticals (pharmacology), Rats, Sprague-Dawley, Stroke (diagnostic imaging), Stroke (pathology), Tissue Distribution (drug effects).
- MESH :
- chemical , analogs & derivatives : Methylmalonic Acid.
- chemical , blood : Caspase Inhibitors, Radiopharmaceuticals.
- chemical , chemistry : Isatin.
- chemical , metabolism : Caspase 3, Caspase 7.
- diagnostic imaging : Stroke.
- drug effects : Apoptosis, Tissue Distribution.
- methods : Molecular Imaging.
- pathology : Stroke.
- chemical , pharmacokinetics : Caspase Inhibitors, Methylmalonic Acid, Radiopharmaceuticals.
- chemical , pharmacology : Caspase Inhibitors, Isatin, Methylmalonic Acid, Radiopharmaceuticals.
- Animals, Disease Models, Animal, Male, Radionuclide Imaging, Rats, Sprague-Dawley.
Abstract
The first biological evaluation of two potent fluorine-18 radiolabelled inhibitors of caspase-3/7 was achieved in a cerebral stroke rat model to visualize apoptosis.
DOI: 10.1007/s11307-015-0865-1
PubMed: 26013478
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002277
Links to Exploration step
pubmed:26013478Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.</title><author><name sortKey="Medoc, Marie" sort="Medoc, Marie" uniqKey="Medoc M" first="Marie" last="Médoc">Marie Médoc</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Dhilly, Martine" sort="Dhilly, Martine" uniqKey="Dhilly M" first="Martine" last="Dhilly">Martine Dhilly</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Matesic, Lidia" sort="Matesic, Lidia" uniqKey="Matesic L" first="Lidia" last="Matesic">Lidia Matesic</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Toutain, Jerome" sort="Toutain, Jerome" uniqKey="Toutain J" first="Jérôme" last="Toutain">Jérôme Toutain</name><affiliation wicri:level="1"><nlm:affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Krause Heuer, Anwen M" sort="Krause Heuer, Anwen M" uniqKey="Krause Heuer A" first="Anwen M" last="Krause-Heuer">Anwen M. Krause-Heuer</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Delamare, Jerome" sort="Delamare, Jerome" uniqKey="Delamare J" first="Jérôme" last="Delamare">Jérôme Delamare</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Fraser, Benjamin H" sort="Fraser, Benjamin H" uniqKey="Fraser B" first="Benjamin H" last="Fraser">Benjamin H. Fraser</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Touzani, Omar" sort="Touzani, Omar" uniqKey="Touzani O" first="Omar" last="Touzani">Omar Touzani</name><affiliation wicri:level="1"><nlm:affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Barre, Louisa" sort="Barre, Louisa" uniqKey="Barre L" first="Louisa" last="Barré">Louisa Barré</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Greguric, Ivan" sort="Greguric, Ivan" uniqKey="Greguric I" first="Ivan" last="Greguric">Ivan Greguric</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Sobrio, Franck" sort="Sobrio, Franck" uniqKey="Sobrio F" first="Franck" last="Sobrio">Franck Sobrio</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France. sobrio@cyceron.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26013478</idno><idno type="pmid">26013478</idno><idno type="doi">10.1007/s11307-015-0865-1</idno><idno type="wicri:Area/PubMed/Corpus">002277</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002277</idno><idno type="wicri:Area/PubMed/Curation">002251</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002251</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.</title><author><name sortKey="Medoc, Marie" sort="Medoc, Marie" uniqKey="Medoc M" first="Marie" last="Médoc">Marie Médoc</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Dhilly, Martine" sort="Dhilly, Martine" uniqKey="Dhilly M" first="Martine" last="Dhilly">Martine Dhilly</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Matesic, Lidia" sort="Matesic, Lidia" uniqKey="Matesic L" first="Lidia" last="Matesic">Lidia Matesic</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Toutain, Jerome" sort="Toutain, Jerome" uniqKey="Toutain J" first="Jérôme" last="Toutain">Jérôme Toutain</name><affiliation wicri:level="1"><nlm:affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Krause Heuer, Anwen M" sort="Krause Heuer, Anwen M" uniqKey="Krause Heuer A" first="Anwen M" last="Krause-Heuer">Anwen M. Krause-Heuer</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Delamare, Jerome" sort="Delamare, Jerome" uniqKey="Delamare J" first="Jérôme" last="Delamare">Jérôme Delamare</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Fraser, Benjamin H" sort="Fraser, Benjamin H" uniqKey="Fraser B" first="Benjamin H" last="Fraser">Benjamin H. Fraser</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Touzani, Omar" sort="Touzani, Omar" uniqKey="Touzani O" first="Omar" last="Touzani">Omar Touzani</name><affiliation wicri:level="1"><nlm:affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Barre, Louisa" sort="Barre, Louisa" uniqKey="Barre L" first="Louisa" last="Barré">Louisa Barré</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author><author><name sortKey="Greguric, Ivan" sort="Greguric, Ivan" uniqKey="Greguric I" first="Ivan" last="Greguric">Ivan Greguric</name><affiliation wicri:level="1"><nlm:affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232</wicri:regionArea></affiliation></author><author><name sortKey="Sobrio, Franck" sort="Sobrio, Franck" uniqKey="Sobrio F" first="Franck" last="Sobrio">Franck Sobrio</name><affiliation wicri:level="1"><nlm:affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France. sobrio@cyceron.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen</wicri:regionArea></affiliation></author></analytic><series><title level="j">Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</title><idno type="eISSN">1860-2002</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Apoptosis (drug effects)</term><term>Caspase 3 (metabolism)</term><term>Caspase 7 (metabolism)</term><term>Caspase Inhibitors (blood)</term><term>Caspase Inhibitors (pharmacokinetics)</term><term>Caspase Inhibitors (pharmacology)</term><term>Disease Models, Animal</term><term>Isatin (chemistry)</term><term>Isatin (pharmacology)</term><term>Male</term><term>Methylmalonic Acid (analogs & derivatives)</term><term>Methylmalonic Acid (pharmacokinetics)</term><term>Methylmalonic Acid (pharmacology)</term><term>Molecular Imaging (methods)</term><term>Radionuclide Imaging</term><term>Radiopharmaceuticals (blood)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Radiopharmaceuticals (pharmacology)</term><term>Rats, Sprague-Dawley</term><term>Stroke (diagnostic imaging)</term><term>Stroke (pathology)</term><term>Tissue Distribution (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral (anatomopathologie)</term><term>Accident vasculaire cérébral (imagerie diagnostique)</term><term>Acide méthyl-malonique (analogues et dérivés)</term><term>Acide méthyl-malonique (pharmacocinétique)</term><term>Acide méthyl-malonique (pharmacologie)</term><term>Animaux</term><term>Apoptose ()</term><term>Caspase-3 (métabolisme)</term><term>Caspase-7 (métabolisme)</term><term>Imagerie moléculaire ()</term><term>Inhibiteurs des caspases (pharmacocinétique)</term><term>Inhibiteurs des caspases (pharmacologie)</term><term>Inhibiteurs des caspases (sang)</term><term>Isatine ()</term><term>Isatine (pharmacologie)</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Radiopharmaceutiques (pharmacocinétique)</term><term>Radiopharmaceutiques (pharmacologie)</term><term>Radiopharmaceutiques (sang)</term><term>Rat Sprague-Dawley</term><term>Répartition dans les tissus ()</term><term>Scintigraphie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Methylmalonic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Caspase Inhibitors</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Isatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Caspase 3</term><term>Caspase 7</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide méthyl-malonique</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Accident vasculaire cérébral</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Accident vasculaire cérébral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Imaging</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Caspase-3</term><term>Caspase-7</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Acide méthyl-malonique</term><term>Inhibiteurs des caspases</term><term>Radiopharmaceutiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Caspase Inhibitors</term><term>Methylmalonic Acid</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide méthyl-malonique</term><term>Inhibiteurs des caspases</term><term>Isatine</term><term>Radiopharmaceutiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Caspase Inhibitors</term><term>Isatin</term><term>Methylmalonic Acid</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Inhibiteurs des caspases</term><term>Radiopharmaceutiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Male</term><term>Radionuclide Imaging</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Apoptose</term><term>Imagerie moléculaire</term><term>Isatine</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Rat Sprague-Dawley</term><term>Répartition dans les tissus</term><term>Scintigraphie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The first biological evaluation of two potent fluorine-18 radiolabelled inhibitors of caspase-3/7 was achieved in a cerebral stroke rat model to visualize apoptosis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26013478</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>22</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1860-2002</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</Title><ISOAbbreviation>Mol Imaging Biol</ISOAbbreviation></Journal><ArticleTitle>In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.</ArticleTitle><Pagination><MedlinePgn>117-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11307-015-0865-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The first biological evaluation of two potent fluorine-18 radiolabelled inhibitors of caspase-3/7 was achieved in a cerebral stroke rat model to visualize apoptosis.</AbstractText><AbstractText Label="PROCEDURES" NlmCategory="METHODS">In vivo characteristics of isatins [(18)F]-2 and [(18)F]-3 were studied and compared by μPET to previously described 1-[4-(2-[(18)F]fluoroethyl)benzyl]-5-(2-methoxymethylpyrrolidin-1-ylsulfonyl)isatin ([(18)F]-1) and to 2-(5-[(18)F]fluoropentyl)-2-methyl-malonic acid ([(18)F]ML-10) used as a reference radiotracer in a rat stroke model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">[(18)F]-2 and [(18)F]-3 were radiolabelled with high radiochemical purity and high specific radioactivity. Radioactivity uptakes in ischemic and contralateral brain regions were weak for the three radiolabelled isatins and lower for [(18)F]ML-10. In μPET, time activity curves showed significant uptake differences between both regions of interest for [(18)F]-1 after 45 min. No differences were observed for [(18)F]ML-10.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Radiolabelled isatins are more promising radiotracers to image apoptosis than [(18)F]ML-10 in this stroke animal model without craniectomy. In particular, [(18)F]-1 presented significant uptake in apoptotic area 45 min after administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Médoc</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhilly</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matesic</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toutain</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krause-Heuer</LastName><ForeName>Anwen M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delamare</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Benjamin H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touzani</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barré</LastName><ForeName>Louisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greguric</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Life Sciences Division, Australian Nuclear Science and Technology Organisation, Kirrawee DC, NSW, 2232, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobrio</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CEA, I2BM, LDM-TEP, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France. sobrio@cyceron.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6301 ISTCT, GIP Cyceron, F-14074, Caen, France. sobrio@cyceron.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université de Caen Basse-Normandie, UMR 6301 ISTCT, GIP Cyceron, BP 5229, F-14074, Caen, France. sobrio@cyceron.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Imaging Biol</MedlineTA><NlmUniqueID>101125610</NlmUniqueID><ISSNLinking>1536-1632</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C532430">5-fluoropentyl-2-methylmalonic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>82X95S7M06</RegistryNumber><NameOfSubstance UI="D007510">Isatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8LL8S712J7</RegistryNumber><NameOfSubstance UI="D008764">Methylmalonic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053179">Caspase 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Anal Chem. 2011 Jul 1;83(13):5415-21</RefSource><PMID Version="1">21615156</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2008 Sep;49(9):1520-8</RefSource><PMID Version="1">18703595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Neurol Sci. 1999 Nov;26(4):298-304</RefSource><PMID Version="1">10563216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Q J Nucl Med Mol Imaging. 2007 Mar;51(1):67-73</RefSource><PMID Version="1">17372575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Chem. 2006 Nov 16;49(23):6704-15</RefSource><PMID Version="1">17154501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16375-80</RefSource><PMID Version="1">19805307</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stroke. 1989 Jan;20(1):84-91</RefSource><PMID Version="1">2643202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Am Thorac Soc. 2009 Aug 15;6(5):469-76</RefSource><PMID Version="1">19687221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Transl Oncol. 2014 Feb 01;7(1):111-9</RefSource><PMID Version="1">24772214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Nov;51(11):1659-62</RefSource><PMID Version="1">20956479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2011 Nov;132(2):180-95</RefSource><PMID Version="1">21807025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Life Sci. 2006 Jan 11;78(7):704-12</RefSource><PMID Version="1">16139848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Q J Nucl Med Mol Imaging. 2013 Jun;57(2):187-200</RefSource><PMID Version="1">23389693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Jul 15;19(14 ):3914-24</RefSource><PMID Version="1">23729364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1400-8</RefSource><PMID Version="1">22699524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucl Med Biol. 2012 Jan;39(1):137-44</RefSource><PMID Version="1">22033021</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Org Biomol Chem. 2009 Apr 7;7(7):1337-48</RefSource><PMID Version="1">19300818</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Labelled Comp Radiopharm. 2013 May 15;56(5):289-94</RefSource><PMID Version="1">24285373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Pharm Des. 2011;17(3):215-29</RefSource><PMID Version="1">21348825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomed Rep. 2013 Nov;1(6):861-867</RefSource><PMID Version="1">24649043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2011 May;52(5):720-5</RefSource><PMID Version="1">21498526</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Behav. 2014 Mar;4(2):312-5</RefSource><PMID Version="1">24683522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41</RefSource><PMID Version="1">18073771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cerebrovasc Dis. 2011;32(4):307-20</RefSource><PMID Version="1">21921593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Imaging Biol. 2013 Feb;15(1):12-8</RefSource><PMID Version="1">22752653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Res. 2009 May;19(5):625-37</RefSource><PMID Version="1">19223854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Mar 11;9(3):e91694</RefSource><PMID Version="1">24618809</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2013 Sep;54(9):1551-6</RefSource><PMID Version="1">23949910</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Imaging Biol. 2015 Jun;17 (3):384-93</RefSource><PMID Version="1">25344147</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1996 Nov 11;739(1-2):88-96</RefSource><PMID Version="1">8955928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anticancer Agents Med Chem. 2009 Nov;9(9):968-85</RefSource><PMID Version="1">19663786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neuropathol. 1985;68(2):122-9</RefSource><PMID Version="1">3907257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Jun;51(6):837-40</RefSource><PMID Version="1">20484422</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2009 Jul 14;1280:158-65</RefSource><PMID Version="1">19450568</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 1996 Mar;16(2):186-94</RefSource><PMID Version="1">8594049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Imaging. 2011 Oct;10(5):340-58</RefSource><PMID Version="1">21521554</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053179" MajorTopicYN="N">Caspase 7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="N">Caspase Inhibitors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007510" MajorTopicYN="N">Isatin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008764" MajorTopicYN="N">Methylmalonic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057054" MajorTopicYN="N">Molecular Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Caspase-3 inhibitors</Keyword><Keyword MajorTopicYN="N">Cerebral stroke</Keyword><Keyword MajorTopicYN="N">Fluorine-18</Keyword><Keyword MajorTopicYN="N">In vivo evaluation</Keyword><Keyword MajorTopicYN="N">Isatins</Keyword><Keyword MajorTopicYN="N">Ischemia</Keyword><Keyword MajorTopicYN="N">PET</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26013478</ArticleId><ArticleId IdType="doi">10.1007/s11307-015-0865-1</ArticleId><ArticleId IdType="pii">10.1007/s11307-015-0865-1</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002251 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002251 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26013478
|texte= In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26013478" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |